CLN3 Disease
Symptoms, Doctors, Treatments, Advances & More

Learn About CLN3 Disease

What is the definition of CLN3 Disease?

CLN3 disease is an inherited disorder that primarily affects the nervous system. After 4 to 6 years of normal development, children with this condition develop vision impairment, intellectual disability, movement problems, speech difficulties, and seizures, which worsen over time.

What are the causes of CLN3 Disease?

CLN3 disease is caused by mutations in the CLN3 gene, which provides instructions for making a protein that is found in tissues throughout the body. The CLN3 protein is part of many compartments within cells, including lysosomes, which are cellular compartments that digest and recycle different types of molecules. However, the exact function of the CLN3 protein is unclear. Research has shown that this protein is involved in many cellular processes, but it is uncertain which of them is the primary role of the protein, or if these processes instead represent downstream effects.

How prevalent is CLN3 Disease?

CLN3 disease is the most common type of NCL, but its exact prevalence is unknown; more than 400 cases have been described in the scientific literature. Collectively, all forms of NCL affect an estimated 1 in 100,000 individuals worldwide.

Is CLN3 Disease an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top CLN3 Disease Local Doctors?
Elite in CLN3 Disease
Elite in CLN3 Disease
Referral may be required
Hamburg, HH, DE 

Angela Schulz practices practicing medicine in Hamburg, Germany. Ms. Schulz is rated as an Elite expert by MediFind in the treatment of CLN3 Disease. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses CLN2 Disease, CLN1 Disease, CLN4 Disease, and CLN5 Disease.

Elite in CLN3 Disease
Elite in CLN3 Disease
Referral may be required
London, ENG, GB 

Sara Mole practices practicing medicine in London, United Kingdom. Ms. Mole is rated as an Elite expert by MediFind in the treatment of CLN3 Disease. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses CLN2 Disease, CLN1 Disease, CLN4 Disease, and CLN5 Disease.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in CLN3 Disease
Elite in CLN3 Disease
Referral may be required
Xinxiang, CN 

Zhongjian Zhang practices practicing medicine in Xinxiang, China. Zhang is rated as an Elite expert by MediFind in the treatment of CLN3 Disease. They are also highly rated in 6 other conditions, according to our data. Their clinical expertise encompasses Batten Disease, CLN4 Disease, CLN5 Disease, and CLN3 Disease.

What are the latest CLN3 Disease Clinical Trials?
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) and CLN3-Related Conditions

Background: CLN3, or Batten disease, is a genetic disorder. This deadly disease leads to decline of brain and nervous system functions. Symptoms of CLN3 typically occur between 4 and 7 years of age. They include changes in how a person sees, thinks, and moves. CLN3 can also cause seizures. No effective treatments for the disease are yet known. There is limited testing of potential therapies. Researchers want ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells

Summary: The primary objective of the study is to determine the safety and feasibility of intrathecal administration of DUOC-01 in patients who are undergoing standard treatment with umbilical cord blood transplant (UCBT) for inborn errors of metabolism and who have evidence of early demyelinating disease in the central nervous system (CNS). The secondary objective of the study is to describe the efficacy ...

Who are the sources who wrote this article ?

Published Date: February 16, 2021
Published By: National Institutes of Health